Trial · NCT01253369

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT01253369, Phase 2, Completed, Dana-Farber Cancer Institute; results first posted 2016-01-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer. Trials, record NCT01253369. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01253369

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
NCT number: NCT01253369
Status: Completed
Phases: Phase 2
Enrollment: 33 participants, actual
Lead sponsor: Dana-Farber Cancer Institute
Conditions: Small Cell Lung Cancer, Lung Cancer, SCLC
Interventions: Pazopanib
First posted: 2010-12-03
Last updated: 2019-04-23
Results first posted: 2016-01-12

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	8-Week Progression-Free Rate	For this endpoint, disease was evaluated radiologically at baseline and week 8 on treatment; Treatment continued until disease progression or unacceptable toxicity. Treatment duration was a median of 3 cycles range (1-20).	The 8-week progression free rate (PFR) was defined as achieving complete response (CR), partial response (PR) or stable disease (SD) based on RECIST 1.1 criteria by the time of the first disease assessment (8 weeks). Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions; PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD; and SD is neither sufficient decrease to qualify as PR nor sufficient increase to qualify as progressive disease (PD). PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. Response needed confirmation within 4 weeks. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions.
Secondary	Objective Response Rate	Disease was evaluated radiologically at baseline and every 8 weeks on treatment; Treatment continued until disease progression or unacceptable toxicity. Treatment duration was a median of 3 cycles range (1-20).	The objective response rate (ORR) was defined as achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better objective response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	8-Week Progression-Free Rate	For this endpoint, disease was evaluated radiologically at baseline and week 8 on treatment; Treatment continued until disease progression or unacceptable toxicity. Treatment duration was a median of 3 cycles range (1-20).	The analysis dataset is comprised of evaluable patients. Patients who had measurable disease at baseline, received at least 1 cycle of therapy and had their disease re-evaluated were considered evaluable for response.	proportion of patients	NUMBER
SECONDARY	Objective Response Rate	Disease was evaluated radiologically at baseline and every 8 weeks on treatment; Treatment continued until disease progression or unacceptable toxicity. Treatment duration was a median of 3 cycles range (1-20).	The analysis dataset is comprised of evaluable patients. Patients who had measurable disease at baseline, received at least 1 cycle of therapy and had their disease re-evaluated were considered evaluable for response.	proportion of patients	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
8-Week Progression-Free Rate	Pazopanib		0.567	80% Confidence Interval 0.434 to 0.692	proportion of patients
Objective Response Rate	Pazopanib		0.033	80% Confidence Interval 0.004 to 0.124	proportion of patients

Source ClinicalTrials.gov

Participant flow4

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pazopanib	33
Overall Study	Evaluable	Pazopanib	30
Overall Study	COMPLETED	Pazopanib	0
Overall Study	NOT COMPLETED	Pazopanib	33

Source ClinicalTrials.gov

Adverse events71

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Pazopanib	3	33
other	Blood and lymphatic system disorders - Other, specify	Blood and lymphatic system disorders	Pazopanib	5	33
other	Cardiac disorders - Other, specify	Cardiac disorders	Pazopanib	6	33
other	Supraventricular tachycardia	Cardiac disorders	Pazopanib	2	33
other	Endocrine disorders - Other, specify	Endocrine disorders	Pazopanib	1	33
other	Hypothyroidism	Endocrine disorders	Pazopanib	3	33
other	Watering eyes	Eye disorders	Pazopanib	1	33
other	Abdominal pain	Gastrointestinal disorders	Pazopanib	4	33
other	Constipation	Gastrointestinal disorders	Pazopanib	2	33
other	Diarrhea	Gastrointestinal disorders	Pazopanib	15	33

1 to 10 of 71Source ClinicalTrials.gov

See all 71 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pazopanib
Total, other adverse events	Pazopanib	26	33
Total, serious adverse events	Pazopanib	12	33

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01253369

GET https://conductscience.org/api/trials/v1/NCT01253369/events?page=2

API reference For AI assistants